When used in combination with primary radiation for locally advanced or high-risk localized disease, ADT is associated with improved disease-free and overall survival.2, 3 However, due to the marked reduction in circulating testosterone, ADT is associated with detrimental changes to body composition, lipid profile and insulin sensitivity.1 Such components comprise the cardiometabolic condition known as metabolic syndrome (MetS). This evidence concerns the gene INS and metabolic syndrome.